Hansa Biopharma has encouraging early clinical results showing its drug imlifidase, used as a pretreatment, enabled Duchenne muscular dystrophy patients to receive the gene therapy Elevidys. Sarepta is searching for ways to mitigate excessive immune responses to Elevidys that can lead to serious and potentially fatal liver injury.
The post Sarepta’s Future in Gene Therapy Remains Clouded, But Data From Partner Hansa Is a Bright Spot appeared first on MedCity News.
